Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy

Area of Science:

• Oncology
• Immunology
• Metabolic Research

Background:

• Immune checkpoint inhibitors (ICIs) offer therapeutic benefits for advanced solid cancers.
• However, low response rates, drug resistance, and adverse effects limit their clinical application.
• T-cell exhaustion, a complex process, underlies the heterogeneous responses to ICI therapy.

Purpose of the Study:

• To review the interplay between T-cell metabolic reprogramming and ICI efficacy.
• To summarize strategies targeting T-cell metabolism to enhance ICI therapy.
• To highlight the potential for metabolic targets in predicting ICI response.

Main Methods:

• Literature review focusing on T-cell metabolism and ICI therapy.
• Analysis of mechanisms linking metabolic reprogramming to T-cell exhaustion.
• Synthesis of recent findings on metabolic interventions combined with ICIs.

Main Results:

• T-cell metabolic disruption is increasingly recognized as a factor limiting ICI effectiveness.
• Metabolic reprogramming offers a novel approach to reverse T-cell exhaustion in the tumor microenvironment.
• Targeting T-cell metabolism can potentially improve drug tolerance and anti-tumor effects.

Conclusions:

• Modulating T-cell metabolism alongside ICIs presents a promising strategy to enhance anti-cancer immunity.
• Identifying metabolic targets could lead to biomarkers for predicting patient response to ICI therapy.
• Further research into T-cell metabolism is crucial for advancing ICI treatment efficacy and overcoming resistance.